Related content

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

By Nyhlin H.   Bang C.   Elsborg L.   Silvennoinen J.   Holme I.   Rüegg P.   Jones J.   Wagner A.  

Scandinavian Journal of Gastroenterology, Vol. 39, Iss. 2, 2004-02 ,pp. : 119-126

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study


By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 7, Iss. 1, 2017-05 ,pp. : 136-142

Karger

Access to resources Recommend Favorite

A Randomized, Double-Blind Placebo-Controlled Trial of Iron in Restless Legs Syndrome

By  

European Neurology, Vol. 43, Iss. 2, 2000-02 ,pp. : 70-75

Karger

Access to resources Recommend Favorite

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks

By Anekthananon T.   Pukritayakamee S.   Ratanasuwan W.   Jittamala P.   Werarak P.   Charunwatthana P.   Suwanagool S.   Lawpoolsri S.   Stepniewska K.   Sapchookul P.   Puthavathana P.   Fukuda C.   Lindegardh N.   Tarning J.   White N. J.   Day N.   Taylor W. R. J.  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 3, 2013-03 ,pp. : 697-707

Oxford University Press

Access to resources Recommend Favorite

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite